SanBio BV
Private Company
Total funding raised: $75M
Overview
Founded in 2001 and headquartered in Utrecht, Netherlands, SanBio BV operates as a hybrid business model combining distribution services with in-house manufacturing of research antibodies. The company generates revenue by distributing products across numerous life science sectors—including immunology, genomics, cell biology, and forensic science—while developing its proprietary MONOSAN antibody brand. As a private, commercial-stage company, it focuses on building long-term relationships with clients and suppliers in the BeNeLux market, emphasizing customer service and technical expertise rather than therapeutic drug development.
Technology Platform
Integrated distribution network and proprietary antibody (MONOSAN) manufacturing for life science research and diagnostic reagents.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
SanBio competes in the fragmented life science distribution market, facing giants like Thermo Fisher and Merck as well as other regional distributors. Its differentiation is based on personalized customer service, technical expertise, and its proprietary MONOSAN antibody line, targeting clients who value local support over purely transactional relationships.